Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 9/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298472 | 0.93 | ESR1 (0.43) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL22718914 | 0.84 | KCNJ1 (0.35) | KCNJ1KCNH2DRD2DRD3 | |
| SCHEMBL24362713 | 0.76 | KDM4E (0.36) | DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL18530864 | 0.73 | KCNJ1 (0.53) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL16862406 | 0.71 | MAOA (0.56) | DRD2DRD4DRD3ALDH1A1LMNA | |
| SCHEMBL20539283 | 0.71 | DRD2 (0.44) | DRD2DRD4DRD3 | |
| SCHEMBL21620884 | 0.71 | KDM4E (0.42) | DRD2DRD4DRD3 | |
| SCHEMBL20231933 | 0.70 | KCNJ1 (0.60) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15036782 | 0.69 | KCNJ1 (0.64) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL17442906 | 0.69 | KCNJ1 (0.52) | KCNJ1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976027-B1 | QUINOLINE DERIVATIVES AS FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12304899-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-05-20 | — | — | US | disclosed |
| EP-3083573-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3976027-A1 | FACTOR XI ACTIVATION INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3255993-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3212619-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3250204-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3212618-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-2773199-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-07-24 | — | — | US | disclosed |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673920-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2014015495-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014018764-A1 | SPIRO - FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129379-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304899-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | KCNJ1 2770/4885KCNH2 2681/4885ACHE 1827/4885 |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | F11, TFPI, F13B | KCNJ1 2770/4885KCNH2 2681/4885ACHE 1827/4885 |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 14/4885ACHE 4837/4885 |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 16/4885ACHE 4836/4885 |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 16/4885ACHE 4849/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 16/4885ACHE 4836/4885 |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 22/4885ACHE 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.